Acute Myeloid Leukemia (AML) Therapeutics

Global Market Trajectory & Analytics

MCP-6847

EXECUTIVE ENGAGEMENTS

OUTREACH

5362
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

858
Interactions with Platform & by Email

PARTICIPANTS

161
Unique # Participated

VALIDATIONS

72
Responses Validated*

COMPETITORS

34
Responses Validated*

BRANDS

903
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

123

PAGES

187

EDITION

16

PRICE

USD $5450


  

HIGHLIGHTS

Amid the COVID-19 crisis, the global market for Acute Myeloid Leukemia (AML) Therapeutics estimated at US$777.8 Thousand in the year 2020, is projected to reach a revised size of US$1.8 Million by 2027, growing at a CAGR of 12.9% over the analysis period 2020-2027. Cytarabine, one of the segments analyzed in the report, is projected to record a 16.7% CAGR and reach US$698.7 Thousand by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anthracycline Drugs segment is readjusted to a revised 14% CAGR for the next 7-year period.
The Acute Myeloid Leukemia (AML) Therapeutics market in the U.S. is estimated at US$209.4 Thousand in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$421.6 Thousand by the year 2027 trailing a CAGR of 17.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.7% and 11.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.2% CAGR.
In the global Tyrosine Kinase Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$79.6 Thousand in the year 2020 will reach a projected size of US$145.7 Thousand by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$269 Thousand by the year 2027, while Latin America will expand at a 11.1% CAGR through the analysis period.

SELECT PLAYERS

AbbVie Inc.; Agios Pharmaceuticals, Inc.; Amgen Inc.; Astellas Pharma Inc.; Astex Pharmaceuticals, Inc.; Celgene Corporation; CTI BioPharma Corp.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo Company Limited; F. Hoffmann-La Roche AG; Immune Pharmaceuticals Inc.; Janssen-Cilag Limited; Jazz Pharmaceuticals plc; MEI Pharma, Inc.; Novartis AG; Pfizer Inc.; Seattle Genetics, Inc.; Stemline Therapeutics, Inc.; Sunesis Pharmaceuticals, Inc.; Tolero Pharmaceuticals, Inc.

SEGMENTS

» Chemotherapy Type (Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites, Other Chemotherapy Types)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
A Prelude
Recent Market Activity
Growing Incidence and Poor Prognosis - A Fatal Concoction Creating Significant Unmet Needs
Inadequacies Marr Existing Therapeutics; Pipeline Therapies Offer Hope
Current and Future Analysis
Standard Mode of Treatment for AML - An Overview
Standard Approved Mode of Therapy for AML by Age Group
List of FDA-Approved Chemotherapy Drugs for Treatment of AML
Ballooning Elderly Population: The Vital Growth Driver for AML Therapeutics
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
AbbVie Inc. (USA)
Actinium Pharmaceuticals, Inc. (USA)
Agios Pharmaceuticals, Inc. (USA)
Amgen Inc. (USA)
Astellas Pharma Inc. (Japan)
Astex Pharmaceuticals, Inc. (USA)
Celgene Corporation (USA)
CTI BioPharma Corp. (USA)
Cyclacel Pharmaceuticals, Inc. (USA)
Daiichi Sankyo Company Limited (Japan)
F. Hoffmann-La Roche AG (Switzerland)
Immune Pharmaceuticals Inc. (USA)
Janssen-Cilag Limited (UK)
Jazz Pharmaceuticals plc (Ireland)
MEI Pharma, Inc. (USA)
Merus N.V. (The Netherlands)
Novartis AG (Switzerland)
Pfizer Inc. (USA)
Seattle Genetics, Inc. (USA)
Stemline Therapeutics, Inc. (USA)
Sunesis Pharmaceuticals, Inc. (USA)
Tolero Pharmaceuticals, Inc. (USA)
3. MARKET TRENDS & DRIVERS
Growing Interest in the Genetics of AML
Targeted Therapies Hog Limelight in AML Therapeutic Pipeline
Select Major AML Therapeutics in Late-Stage Clinical Development
Select AML Therapeutics in Phase I and II Clinical Development
FLT3 - The Most Advanced Natural Target
Chemotherapy Retains Developers’ Interest; Better Chemotherapies on the Horizon
Vyxeos - The New Standard of Care in AML Treatment?
Select Benefits of Vyxeos in a Gist:
Drug Targeting Mutant IDH2 Enzyme Enters Pivotal Trials
Immunotherapies in Development too Show Promise
Annamycin Shows Promise as a Second Line Therapy for AML
Volasertib - the First in Molecular Targeting Agents for AML to Advance in Clinical Trials
ADCs’ Clinical Trials Depict Mixed Results
Research Innovations/Findings in AML Therapeutics
Anti-CD98 Antibodies Offer Novel Approach
Inhibition of Metabolic Enzyme in AML Pathway Identified as an Promising Option
Personalized Vaccine Approach Invades AML Therapeutic R&D
Ceramide-based Therapeutic Targets Drug Resistance of AML
Fructose - Potential Target for AML Therapeutics
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Cytarabine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Cytarabine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cytarabine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Anthracycline Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Anthracycline Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anthracycline Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Alkylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Anti-Metabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Anti-Metabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anti-Metabolites by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Chemotherapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Other Chemotherapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Chemotherapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
USA Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
China Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
France Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UK Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
SPAIN
Spain Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
RUSSIA
Russia Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
AUSTRALIA
Australia Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
INDIA
India Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
India Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
SOUTH KOREA
South Korea Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
LATIN AMERICA
Latin America Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
Latin America Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
Latin America Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
ARGENTINA
Argentina Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
BRAZIL
Brazil Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
MEXICO
Mexico Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
REST OF LATIN AMERICA
Rest of Latin America Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
MIDDLE EAST
Middle East Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
Middle East Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
Middle East Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
IRAN
Iran Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
ISRAEL
Israel Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
SAUDI ARABIA
Saudi Arabia Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
UNITED ARAB EMIRATES
UAE Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
REST OF MIDDLE EAST
Rest of Middle East Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
AFRICA
Africa Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2020 & 2027
Total Companies Profiled: 34

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com